GO
Loading...

On the Line: BioMarin Pharma's CEO Jean Jacques Bienaime

Thursday, 11 Oct 2007 | 10:38 AM ET

BioMarin Pharmaceuticals should be profitable next year, CEO Jean Jacques Bienaime told Cramer Wednesday on Mad Money, thanks to the expected approval of a new drug.

BioMarin Pharmaceutical CEO
Talking with Jean Jacques Bienaime, BioMarin Pharmaceutical CEO, and Mad Money host Jim Cramer.

The drug, Kuvan, has priority-review status with the Food & Drug Administration because of its "advanced medical need," Bienaime said. That means approval could come as soon as November, possibly putting BioMarin in the black for 2008.

Kuvan is a treatment for a metabolic disorder called phenylketonuria. Fifty thousand people eagerly await the drug’s approval because Kuvan will be the first treatment for the disease outside of a rigid diet.

“BMRN is not done going up,” Cramer said.

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

  Price   Change %Change
BMRN
---

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.